Triple Agonist Peptide Compositions for Glucose and Weight Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents targeting GLP-1, GIP, and glucagon receptors for treating metabolic diseases like diabetes and obesity often cause side effects and have limited efficacy, and there is a need for compositions that can effectively activate these receptors to control blood glucose levels and reduce body weight without adverse effects.
Innovation Solution
Development of triple agonist peptides that bind to GLP-1, GIP, and glucagon receptors, with optional biotin and fatty acid conjugations for improved bioavailability, administered in pharmaceutical formulations to treat obesity, diabetes, and non-alcoholic fatty liver disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic agents targeting GLP-1, GIP, and glucagon receptors are used to treat metabolic diseases, then blood glucose control and weight loss are improved, but side effects increase and efficacy is limited
Solution Approach 1:
The patent combines multiple receptor-targeting functions into a single triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This merging of multiple therapeutic actions into one agent aims to improve overall metabolic control while potentially reducing the cumulative side effects associated with multiple separate medications
Solution Approach 2:
The triple agonist peptide serves multiple therapeutic functions simultaneously: it regulates blood glucose through insulin secretion stimulation, promotes weight loss through appetite suppression, and improves lipid metabolism. This multi-functionality addresses several metabolic disease symptoms with a single agent, improving reliability while managing side effect profiles
2Object-affected harmful factors
If conventional weight loss methods (diet and exercise) are used, then health improvement is achieved, but treatment effectiveness is limited when these methods are not sufficient
Solution Approach 1:
The patent introduces pharmacological intervention that fundamentally changes the therapeutic parameters by directly targeting hormonal receptors involved in metabolism, appetite, and glucose regulation. This shifts the treatment approach from behavioral modifications to biochemical modulation, achieving reliable effectiveness where conventional methods fail
3Reliability
If existing medication or surgery is used for obesity treatment, then weight control is achieved, but efficacy remains limited
Solution Approach 1:
The triple agonist peptide merges multiple therapeutic mechanisms into a single molecular entity, simplifying the treatment approach while improving efficacy. Instead of requiring multiple medications or complex surgical interventions, one agent addresses multiple metabolic pathways simultaneously
Data Source
AI summary
Triple agonist peptides having activities at each of GLP-1, Glucagon and GIP receptors are provided. Triple agonist analogs having one or more biotin moieties and/or fatty acid moieties conjugated thereto for improved bioavailability and pharmacokinetics are also described. Compositions and formulations of these triple agonist peptides are particularly suited for treating, alleviating, and/or preventing one or more metabolic diseases such as obesity, diabetes mellitus, or non-alcoholic fatty liver disease. Compositions and methods of use thereof are also described for treating, alleviating, and/or preventing one or more neurodegenerative disease such as Alzheimer's disease (AD) and Parkinson's disease (PD).